We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Standardizing Biomarker Analysis Across Clinical Testing

Standardizing Biomarker Analysis Across Clinical Testing  content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

NeoGenomics and Definiens have announced that they have expanded their alliance to develop and automate the analysis of new biomarker assays for clinical trials and routine clinical testing.  Under the agreement, Definiens will provide automated quantitative biomarker solutions to support NeoGenomics’ immunohistochemistry services for both its Pharma Services customers and Clinical clients, helping to improve pathology interpretation, standardize the readout (analysis/scoring), and identify the signature for optimal biomarker cut point threshold.

NeoGenomics excels in providing custom developed Immunohistochemistry (IHC) assays to be used in clinical trials, companion diagnostics and clinical testing.  Automated IHC workflows, quantification, and interpretation tools remove variability of pathology scoring criteria and will allow researchers and pathologists a higher level of analytical consistency to standardize biomarker analysis for global clinical trials and clinical testing. 

Douglas VanOort, Chairman & CEO for NeoGenomics commented, “Continual innovation and automation of our testing services helps us provide increasingly more efficient and effective services for our clients.  Our relationship with Definiens has allowed us to further automate some of our important immunohistochemistry services for clinical trials and for clinical testing, and we are looking forward to leveraging this relationship further.  NeoGenomics is committed to being a leader in innovation, and to providing the most advanced and highest-quality testing services for all of our Pharmaceutical and Clinical clients.” 

Thomas Heydler, CEO at Definiens said, “We are excited to further expand our long-lasting relationship with NeoGenomics by introducing cutting-edge solutions to the clinical trial services workflow and to further expand pathology automation used in routine clinical testing.  Our products and services support the development of new assays for clinical trials to help answer the most relevant questions in drug development.  Definiens’ unique solutions also play a key role in helping to make clinical decisions with interpretation of lab developed tests.” 

Thomas Colarusso, VP Business Development and Strategy at Definiens adds, “We expect Definiens Tissue Phenomics solutions will provide strategic value and new insights for existing and novel esoteric biomarker tests that NeoGenomics will use in both routine clinical assays and in clinical trials.”

This article has been republished from materials provided by Definiens. Note: material may have been edited for length and content. For further information, please contact the cited source.